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Abstract
© 2015  MacKenzie  et  al.  Background:  Recent  clinical  studies  show  that  tyrosine  kinase
inhibitors  slow  the  rate  of  lung  function  decline  and  decrease  the  number  of  acute
exacerbations in  patients  with  Idiopathic  Pulmonary Fibrosis  (IPF).  However,  in  the murine
bleomycin model of fibrosis, not all tyrosine kinase signaling is detrimental. Exogenous ligands
Fibroblast Growth Factor (FGF) 7 and 10 improve murine lung repair and increase survival after
injury  via  tyrosine  kinase  FGF  receptor  2b-signaling.  Therefore,  the  level  and  location  of
FGF/FGFR expression as well as the exogenous effect of the most highly expressed FGFR2b
ligand,  FGF1,  was analyzed on human lung fibroblasts.  Methods:  FGF ligand and receptor
expression was evaluated in donor and IPF whole lung homogenates using western blotting and
qPCR. Immunohistochemistry for FGF1 and FGFR1/2/3/4 were performed on human lung tissue.
Lastly, the effects of FGF1, a potent, multi-FGFR ligand, were studied on primary cultures of IPF
and non-IPF donor fibroblasts. Western blots for pro-fibrotic markers, proliferation, FACS for
apoptosis, transwell assays and MetaMorph analyses on cell cultures were performed. Results:
Whole  lung  homogenate  analyses  revealed  decreased  FGFR b-isoform expression,  and  an
increase in FGFR c-isoform expression. Of the FGFR2b-ligands, FGF1 was the most significantly
increased in IPF patients; downstream targets of FGF-signaling, p-ERK1/2 and p-AKT were also
increased.  Immunohistochemistry  revealed  FGF1  co-localization  within  basal  cell  sheets,
myofibroblast foci, and Surfactant protein-C positive alveolar epithelial type-II cells as well as co-
localization with FGFR1, FGFR2, FGFR3, FGFR4 and myofibroblasts expressing the migratory
marker Fascin. Both alone and in the presence of heparin, FGF1 led to increased MAPK-signaling
in  primary  lung  fibroblasts.  While  smooth  muscle  actin  was  unchanged,  heparin  +  FGF1
decreased  collagen  production  in  IPF  fibroblasts.  In  addition,  FGF1  +  heparin  increased
apoptosis  and  cell  migration.  The  FGFR  inhibitor  (PD173074)  attenuated  these  effects.
Conclusions:  Strong  expression  of  FGF1/FGFRs  in  pathogenic  regions  of  IPF  suggest  that
aberrant  FGF1-FGFR  signaling  is  increased  in  IPF  patients  and  may  contribute  to  the
pathogenesis of lung fibrosis by supporting fibroblast migration and increased MAPK-signaling.
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